JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients
Zekri, Abdel-Rahman N; Bakr, Yasser Mabrouk; Ezzat, Maali Mohamed; Zakaria, Mohamed Serag Eldeen; Elbaz, Tamer Mahmoud;
  PDF(new window)
 Abstract
Background: Early detection of various kinds of cancers nowadays is needed including colorectal cancer due to the highly significant effects in improving cancer treatment. The aim of this study was to evaluate the potential value of adiponectin, visfatin and resistin as early biomarkers for colorectal cancer patients. Materials and Methods: Serum levels of adiponectin, visfatin and resistin were measured by a sandwich-enzyme-linked (ELISA) assay technique in 114 serum samples comprising 34 patients with colorectal cancer (CRC), 27 with colonic polyps (CP), 24 with inflammatory bowel disease (IBD) and 29 healthy controls. The diagnostic accuracy of each serum marker was evaluated using receiver-operating characteristic (ROC) curve analysis. Results: The mean concentration of adiponectin was significantly higher in CRC and CP groups than IBD and control groups (P-value <0.05). Also the mean concentration of serum resistin was significantly elevated in the IBD and control groups compared to CRC and CP groups (P-value
 Keywords
Colorectal carcinoma;irritable bowel disease;colonic polyps;adiponectin;visfatin;resistin;
 Language
English
 Cited by
1.
Alteration of Leptin and Adiponectin in Multistep Colorectal Tumorigenesis, Asian Pacific Journal of Cancer Prevention, 2016, 17, 4, 2119  crossref(new windwow)
 References
1.
Stofkova A (2010). Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul, 44, 25-36. crossref(new window)

2.
Akdogan R, Ozgur O, Gucuyeter S, et al (2014). A pilot study of Helicobacter pylori genotypes and cytokine gene polymorphisms in reflux oesophagitis and peptic ulcer disease. Bratisl Lek List, 115, 221-8.

3.
Axelsson J, Bergsten A, Qureshi AR, et al (2006). Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int, 69, 596-604. crossref(new window)

4.
Ayyildiz T, Dolar E, Ugras N, et al (2015). Adipo-R1 and adipo-R2 expression in colorectal adenomas and carcinomas. Asian Pac J Cancer Prev, 16, 367-72. crossref(new window)

5.
Becarevic M, Seferovic J, Ignjatovic S, Singh S M-, N S (2012). Adiponectin non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus. J Med Biochem, 31, 199-204.

6.
Dalamaga M, Karmaniolas K, Panagiotou A, et al (2015). Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control, 20, 193-9.

7.
Dalamaga M, Archondakis S, Sotiropoulos G, et al (2012). Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas, 71, 301-8. crossref(new window)

8.
Erarslan E, Turkay C, Koktener A, et al (2009). Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci, 54, 862-8. crossref(new window)

9.
Fazeli MS, Dashti H, Akbarzadeh S, et al (2013). Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine, 62, 81-5. crossref(new window)

10.
Gado A, Ebeid B, Abdelmohsen A, Axon A (2013). Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? Alexandria J Med. Alexandria University Faculty of Medicine

11.
Gan AM, Butoi ED, Manea A, et al (2013). Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res, 351, 161-74. crossref(new window)

12.
Garten A, Petzold S, Korner A, Imai SI, Kiess W (2009). Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab, 20, 130-8. crossref(new window)

13.
Ghaemmaghami S, Mohaddes SM, Hedayati M, et al (2013). Resistin and visfatin expression in HCT-116 colorectal cancer cell Line. Int J Mol Cell Med, 2, 143-50.

14.
Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12. crossref(new window)

15.
Phelip JM, Bageacu S, Baconnier M (2011). Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer. J Gastrointest Oncol, 2, 232-9.

16.
Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405. crossref(new window)

17.
Karmiris K, Koutroubakis IE, Xidakis C, et al (2006). Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis, 12, 100-5. crossref(new window)

18.
Kaser S, Kaser A, Sandhofer A, et al (2003). Resistin messenger- RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun, 309, 286-90. crossref(new window)

19.
Kralisch S, Klein J, Lossner U, et al (2005). Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol, 185, 1-8. crossref(new window)

20.
Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81. crossref(new window)

21.
Lee ES, Park SH, Kim MS, et al (2012). Caffeic acid disturbs monocyte adhesion onto cultured endothelial cells stimulated by adipokine resistin. J Agric Food Chem, 60, 2730-9. crossref(new window)

22.
Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 15, 401-2. crossref(new window)

23.
MJ T (2002). Cachexia in cancer patients. Nat Rev Cancer, 2, 862-71. crossref(new window)

24.
Nakajima TE, Yamada Y, Hamano T, et al (2010). Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci, 101, 1286-91. crossref(new window)

25.
Otake S, Takeda H, Fujishima S, et al (2010). Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol, 16, 1252-7. crossref(new window)

26.
Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J BC (2005). Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta, 1732, 96-102. crossref(new window)

27.
Slomian G, Swietochowska E, Malinowska-Borowska J, et al (2014). Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Reports, 66, 902-7. crossref(new window)

28.
Tandon K, Imam M, Ismail BES, Castro F (2015). Body mass index and colon cancer screening: the road ahead. World J Gastroenterol, 21, 1371-6. crossref(new window)

29.
Tulubas F, Mete R, Oznur M, Topcu B (2013). The role of adipocytokines in colon cancer and adenomas / uloga adipocitokina u kanceru i adenomima debelog creva. J Med Biochem, 33, 135-42.

30.
Yamaji T, Iwasaki M, Sasazuki S TS (2010). Interaction between adiponectin and leptin Influences the risk of colorectal adenoma. Cancer Res, 70, 5430-7. crossref(new window)

31.
Yu LX, Zhou NN, Liu LY, et al (2014). Adiponectin receptor 1 (ADIPOR1) rs1342387 polymorphism and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 7515-20. crossref(new window)